|
Stopped in week 1
|
4/27 (14.8%)
|
5/25 (20.0%)
|
3/16 (18.8%)
|
2/20 (10.0%)
|
14/88 (15.9%)
|
|
Stopped in week 2
|
14/24 (58.3%)
|
14/20 (70.0%)
|
9/16 (56.3%)
|
15/21 (71.4%)
|
52/81 (64.2%)
|
|
Stopped in week 1 but still experienced moderately bad symptoms
|
2/17 (11.8%)
|
0/16 (0.0%)
|
1/9 (11.1%)
|
1/11 (9.1%)
|
4/53 (7.5%)
|
|
Stopped in week 2 but still experienced moderately bad symptoms
|
5/9 (55.6%)
|
6/9 (66.7%)
|
0/2 (0.0%)
|
4/7 (57.1%)
|
15/27 (55.6%)
|
|
Stopped in week 1 but had not recovered from all symptoms
|
2/20 (10.0%)
|
2/20 (10.0%)
|
1/14 (7.1%)
|
2/17 (11.8%)
|
7/71 (9.9%)
|
|
Stopped in week 2 but had not recovered from all symptoms
|
5/10 (50.0%)
|
6/10 (60.0%)
|
1/8 (12.5%)
|
6/10 (60.0%)
|
18/38 (47.4%)
|
|
Median (IQR) doses taken in week 1
|
20 (17,21)
|
18.5 (17,20)
|
19 (18,21)
|
19 (18, 21)
|
19 (18,21)
|
|
➙Morning
|
6 (6,7)
|
6 (5,6)
|
6 (6,7)
|
6 (6,7)
|
6 (6,7)
|
|
➙Afternoon
|
7 (5,7)
|
6 (5,7)
|
7 (6,7)
|
6.5 (5,7)
|
7 (5,7)
|
|
➙Evening
|
7 (7,7)
|
7 (6,7)
|
7 (6,7)
|
7 (6,7)
|
7 (6,7)
|
